Oramed Pharmaceuticals Inc. · NASDAQ:ORMP
Oramed Pharmaceuticals — Investor Presentation (September 2010)
14 slides from Oramed Pharmaceuticals's investor presentation, Sep 8, 2010
Slide 1: Entera Bio
IED EnteraBio Bringing new speed to drug development.......... Breaking new ground in drug delivery... Aug. 2010 -confidential-
Slide 2: Who We Are
Who We Are Entera Bio is engaged in the Research, Development, and Commercialization of novel large molecule theapeutics. Entera Bio has developed a proprietary platform technology for the oral delivery of new and existing Large Molecule drugs. Entera Bios’ formulations will be the first choice for
Slide 3: Management
Management CEO: Phillip Schwartz, MSc, PhD + >15 years clinical and Basic Research Experience at Dana Farber Cancer Inst.. Harvard Medical School, Weizmann Institute, Rockefeller University. + Mentored by two Nobel laureates and one MacArthur Fellow. + > 10 years of Biotech and Pharmaceutical Experi
Slide 4: Management
Management CMO- Miriam Blum, MD + MD from New York University Medical School. Residency in internal medicine & fellowships in endocrinology & osteoporosis at Mount Sinai Medical Center + — Recipient of multiple research grants in bone metabolism and osteoporosis, as well as the prestigious NIH K23 g
Slide 5: The company
The company Founded in June 2010 by the CEO, Phillip Schwartz, in cooperation with Oramed Pharmaceuticals and DNA Ltd. Entera will be based in the technology park of Hebrew University in Givat Ram, Jerusalem. Entera has licensed technology from Oramed and has signed agreements with additional pharma
Slide 6: Market
Market The drug delivery market is currently valued at >$70 billion and growing at a CAGR of 12%. More than $100 Billion of the blockbuster drug market will go generic by 2013. To replace this revenue Pharma will have to develop more than 100 “usable” large molecule drugs in the next 5 years To fill
Slide 7: Large pharmaceutical companies are currently undergoing massive restructuring
Large pharmaceutical companies are currently undergoing massive restructuring in pursuit of large molecule drug targets * The number of “new” small molecular entities is decreasing at >15% / year as compared to large molecular entities. * More than 60% of the drugs in development are large molecules
Slide 8: Entera delivers drugs effectively
Entera delivers drugs effectively Oral drug delivery is the most straight forward and user friendly approach to medical treatment. Large molecule peptides are hard to absorb and easily inactivated in the Gl tract. By partnering with other biotech’s who have developed and tested novel Ig. molecule dr
Slide 9: Our technology
Our technology Combines 2 well characterized drug delivery entities to increase drug half life and bioavailability = A proprietary synthetic Amino Acid that enables molecular transport of large molecules through the intestinal wall = A proprietary molecular protection prevents drug break down and si
Slide 10: Our Strategy - rapid development, rapid returns
Our Strategy — rapid development, rapid returns..... Use of known therapeutic molecules (no drug discovery). Optimization of proprietary formulations. Agreements with large bio/pharma companies. Next large market product begins development Lean & mean (with outsourcing and flexibility) Experienced t
Slide 11: Operational Business Strategy
Operational Business Strategy v 2 proven delivery technologies applied to insulin o Preliminary experiments with insulin have already shown the 3 fold increase of efficacy of this system in Humans a o All the entities used are either aA FDA approved or GRAS. Fe > Rapidly complete Ph. | trials with o
Slide 12: The next steps
The next steps cans & bio- availablety Small animals Large animal studies- toxicology & Human trial design v July 2010 Milestone Milestone Milestone z 2 a -confidential- 12
Slide 13: Market - Osteoporosis
Market- Osteoporosis Osteoporosis drug market >$8 Billion in 2007 and is expected to reach $12 billion by 2011. More than 80% of the osteoporosis drugs sold are bisphosphinates which slow the resorbtion of bone. + Sales of Fosamax by Merck were $1.8 billion in 2007. Injectable osteoporosis medicatio
Slide 14: Forward-looking statements
This presentation may contain forward-looking statements, including statements regarding the intent, belief or current expectations of Oramed Pharmaceuticals Inc. and affiliates about the market, business, properties, financial condition and results of operations of our 50% indirectly held subsidiar
Oramed Pharmaceuticals — Investor Presentation (September 2010) on 6ix